{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SCLC&page=12",
    "query": {
      "condition": "SCLC",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 4001,
    "total_pages": 401,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SCLC&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SCLC&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T23:20:28.094Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03607682",
      "title": "Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With Extensive-Stage Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Extensive Stage Small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "Tumor Treating Fields (TTF) Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "NovoTTF-200A Device",
          "type": "DEVICE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2018-09-05",
      "completion_date": "2020-07-13",
      "has_results": true,
      "last_update_posted_date": "2020-08-04",
      "last_synced_at": "2026-10-24T23:20:28.094Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03607682"
    },
    {
      "nct_id": "NCT00309959",
      "title": "ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Adenocarcinoma",
        "Cervical Adenosquamous Carcinoma",
        "Cervical Small Cell Carcinoma",
        "Cervical Squamous Cell Carcinoma",
        "Recurrent Cervical Carcinoma"
      ],
      "interventions": [
        {
          "name": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 37,
      "start_date": "2006-11",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2019-01-08",
      "last_synced_at": "2026-10-24T23:20:28.094Z",
      "location_count": 26,
      "location_summary": "Aurora, Colorado • Chicago, Illinois • Urbana, Illinois + 17 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00309959"
    },
    {
      "nct_id": "NCT03552718",
      "title": "QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Breast Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Melanoma",
        "Non Small Cell Lung Cancer",
        "Pancreatic Cancer",
        "Liver Cancer"
      ],
      "interventions": [
        {
          "name": "YE-NEO-001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "NantBioScience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2018-08-10",
      "completion_date": "2025-03-18",
      "has_results": false,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-10-24T23:20:28.094Z",
      "location_count": 1,
      "location_summary": "El Segundo, California",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03552718"
    },
    {
      "nct_id": "NCT03543813",
      "title": "PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Head and Neck Cancer",
        "Non Small Cell Lung Cancer",
        "Diffuse Large B Cell Lymphoma",
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "CX-2029",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytomX Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 133,
      "start_date": "2018-06-15",
      "completion_date": "2023-06-01",
      "has_results": false,
      "last_update_posted_date": "2024-01-23",
      "last_synced_at": "2026-10-24T23:20:28.094Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Encinitas, California • Los Angeles, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03543813"
    },
    {
      "nct_id": "NCT04258813",
      "title": "Onco-primary Care Networking to Support TEAM-based Care",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Blood Pressure",
        "Hypertension",
        "Cancer",
        "Cancer, Breast",
        "Cancer of Prostate",
        "Cancer Colorectal",
        "Cancer, Endometrial",
        "Cancer of Head and Neck",
        "Non Small Cell Lung Cancer",
        "CVD - Cardiovascular Disease",
        "Diabetes Mellitus",
        "Hypercholesterolemia",
        "Diabetes",
        "Cancer of Esophagus",
        "Cancer of Liver",
        "Cancer, Renal Cell",
        "Cancer of Pancreas",
        "Cancer Ovaries"
      ],
      "interventions": [
        {
          "name": "iGuide Intervention (Self-guided)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "iGuide 2 Intervention (Tailored/Targeted)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Control",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 313,
      "start_date": "2021-06-14",
      "completion_date": "2026-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-20",
      "last_synced_at": "2026-10-24T23:20:28.094Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04258813"
    },
    {
      "nct_id": "NCT03664024",
      "title": "Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2018-10-30",
      "completion_date": "2021-11-05",
      "has_results": true,
      "last_update_posted_date": "2024-08-22",
      "last_synced_at": "2026-10-24T23:20:28.094Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Baltimore, Maryland • Detroit, Michigan",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03664024"
    },
    {
      "nct_id": "NCT02659059",
      "title": "Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small-Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Platinum Doublet Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 324,
      "start_date": "2016-02-15",
      "completion_date": "2022-03-07",
      "has_results": true,
      "last_update_posted_date": "2023-04-05",
      "last_synced_at": "2026-10-24T23:20:28.094Z",
      "location_count": 29,
      "location_summary": "San Diego, California • Plainville, Connecticut • Weston, Florida + 19 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Plainville",
          "state": "Connecticut"
        },
        {
          "city": "Weston",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02659059"
    },
    {
      "nct_id": "NCT03371979",
      "title": "Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pegzilarginase",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aeglea Biotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2017-12-21",
      "completion_date": "2021-01-01",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-10-24T23:20:28.094Z",
      "location_count": 21,
      "location_summary": "Mobile, Alabama • Aurora, Colorado • Denver, Colorado + 18 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03371979"
    },
    {
      "nct_id": "NCT06275360",
      "title": "Repositioning Immunotherapy in VetArans With Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2024-03-01",
      "completion_date": "2030-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-10-24T23:20:28.094Z",
      "location_count": 7,
      "location_summary": "West Haven, Connecticut • Washington D.C., District of Columbia • Indianapolis, Indiana + 4 more",
      "locations": [
        {
          "city": "West Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06275360"
    },
    {
      "nct_id": "NCT03910660",
      "title": "A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Neuroendocrine Tumors",
        "Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "BXCL701 plus Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "BXCL701 monotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioXcel Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 98,
      "start_date": "2019-02-12",
      "completion_date": "2025-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-10-24T23:20:28.094Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Denver, Colorado • New Haven, Connecticut + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03910660"
    }
  ]
}